| Kayli Backes, | |
|
3406 Glacier Hwy, Juneau, AK 99801-7251 | |
| (907) 463-3303 | |
| (907) 463-6858 |
| Full Name | Kayli Backes |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 3406 Glacier Hwy, Juneau, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013502996 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kayli Backes, 3406 Glacier Hwy, Juneau, AK 99801-7251 Ph: (907) 463-3303 | Kayli Backes, 3406 Glacier Hwy, Juneau, AK 99801-7251 Ph: (907) 463-3303 |
News Archive
The strength of New Jersey's life sciences community and its unique ability to contribute to one of medicine's fastest growing areas—personalized medicine—has prompted BioNJ, the voice of the biotechnology industry in New Jersey, to create a special Diagnostics Committee.
The Human Immunodeficiency Virus (HIV) is a highly contagious infection usually transmitted through body fluids during sexual contact, blood transfusion, during pregnancy, delivery, and breastfeeding through breast milk. Worldwide, there were about 37.9 million people across the globe with HIV in 2018, and approximately 1.7 million people became newly infected across the globe in 2018 alone.
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes skin inflammation in atopic dermatitis and the characteristic thickening of the skin.
TuBerculosis Vaccine Initiative (TBVI) recently received a $3million grant for a three year term from the Bill & Melinda Gates Foundation. This grant enables the nonprofit organization to strengthen its fundraising and communication activities in order to increase awareness and support for tuberculosis (TB) vaccine research and raise funds for the development of safer and more effective vaccines.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.
› Verified 2 days ago
Sanaz Ghorbanpoor, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3406 Glacier Hwy, Juneau, AK 99801 Phone: 907-463-3303 | |
Lila A Searer, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3406 Glacier Hwy, Juneau, AK 99801 Phone: 907-463-3303 Fax: 907-463-6858 | |
Leslye Ann Galey, LPC Counselor Medicare: Medicare Enrolled Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8498 | |
Justin Parish, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3406 Glacier Hwy, Juneau, AK 99801 Phone: 907-463-3303 | |
Ms. Donna M Zahina, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5594 Aisek St., Juneau, AK 99801 Phone: 907-780-3048 Fax: 907-780-3053 | |
Dany Reyes, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3406 Glacier Hwy, Juneau, AK 99801 Phone: 907-463-3303 Fax: 907-463-6858 |